221 related articles for article (PubMed ID: 12556752)
1. The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.
Weber MA
Rev Cardiovasc Med; 2002; 3(4):183-91. PubMed ID: 12556752
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Leary AC; MacDonald TM
Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
[TBL] [Abstract][Full Text] [Related]
4. [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].
Burnier M; Brunner HR
Therapie; 1998; 53(3):279-84. PubMed ID: 9773127
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
Weber MA; Giles TD
Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
[TBL] [Abstract][Full Text] [Related]
6. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
Johnston CI
Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED; Preddie DC
Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptor antagonists and ACE inhibitors.
Howes LG; Christie N
Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
[TBL] [Abstract][Full Text] [Related]
10. RAS inhibition in hypertension.
Ibrahim MM
J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
[TBL] [Abstract][Full Text] [Related]
11. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
Ruilope LM; Segura J; Schiffrin EL
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):74-9. PubMed ID: 12806588
[TBL] [Abstract][Full Text] [Related]
12. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
Costantino S; Millozzi F; Scarlata S
Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
[No Abstract] [Full Text] [Related]
15. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Lyle PA; Tershakovec AM; Devereux RB; Oparil S; Dahlöf B; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Wedel H
Expert Opin Emerg Drugs; 2005 Nov; 10(4):729-45. PubMed ID: 16262560
[TBL] [Abstract][Full Text] [Related]
16. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
[TBL] [Abstract][Full Text] [Related]
17. [ACE inhibitor or AT1 antagonist. Is there a differential therapy?].
Unger T; Rangoonwala B; Rosenthal J
MMW Fortschr Med; 2002 Jun; 144(24):36-8. PubMed ID: 12134723
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Weber MA
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
[TBL] [Abstract][Full Text] [Related]
19. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
Pourdjabbar A; Lapointe N; Rouleau JL
Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
